Intrinsic value of Amicus Therapeutics, Inc. (FOLD)

[per Chepakovich valuation model]

other valuations of FOLD

[per Chepakovich valuation model]  See other valuations of FOLD stock

Previous Close$9.49
Intrinsic Value
Upside potential
Previous Close
$9.49

VALUATION INPUT DATA

Revenue, mln $
Initial revenue growth rate (norm.), %
Variable cost ratio, %
Fixed operating expenses, mln $
Production assets / Revenue, %
Working capital / Revenue, %
Interest rate on debt, %
Life of production assets, yrs
Initial discount rate, %
Shares outstanding, mln
Adjusted equity ratio
Adjusted assets / Revenue
Based on fiscal year data as of 2020-12-31 and quarterly data as of 2020-12-31.
NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.
  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2020(a)2021202220232024202520262027202820292030203120322033203420352036203720382039204020412042204320442045

INCOME STATEMENT

Revenue growth rate, %43.2NaN
Revenue, $261NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m508NaN
Operating income, $m-247NaN
EBITDA, $m-236NaN
Interest expense (income), $mNaN
Earnings before tax, $m-274NaN
Tax expense, $m3NaN
Net income, $m-277NaN

BALANCE SHEET

Cash and short-term investments, $m483NaN
Total assets, $m887NaN
Adjusted assets (=assets-cash), $m403NaN
Average production assets, $m244NaN
Working capital, $m450NaN
Total debt, $m389NaN
Total liabilities, $m600NaN
Total equity, $m286NaN
Debt-to-equity ratio1.359NaN
Adjusted equity ratio-0.488NaN

CASH FLOW

Net income, $m-277NaN
Depreciation, amort., depletion, $m11NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-233NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-3NaN
Free cash flow, $m-230NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m450
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN